Research programme: methioninase gene therapies - AntiCancer

Drug Profile

Research programme: methioninase gene therapies - AntiCancer

Alternative Names: Adeno MET gene/selenomethionine; Geneceuticals; GFP-bacterial MET gene/selenomethionine; METgene-SeMET; rAd-MET/SeMET

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator AntiCancer
  • Class Antineoplastics; Gene therapies; Oxidants
  • Mechanism of Action Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Cancer

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Cancer in USA (Parenteral)
  • 22 Jun 2011 Research programme: methioninase gene therapies - AntiCancer is available for licensing as of 22 Jun 2011. http://www.anticancer.com
  • 06 Apr 2011 Preclinical toxicology data in Cancer presented at the 102nd Annual Meeting of the American Association for Cancer Research (102nd-AACR-2011)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top